文献速递核素与放射性配体治疗肿瘤 PET/CT

肽受体放射性核素治疗(PRRT)应用的证据基础

Evidence Base for the Use of PRRT.
PubMed 文献 · Semin Nucl Med · 2020-05-24

本文回顾了PRRT在播散性神经内分泌肿瘤(NETs)中从学术构想走向临床实践的漫长历程,指出其转化过程因对药物注册流程严谨性理解不足而历经波折。尽管早期研究存在方案模糊和数据缺失,但逐渐积累的证据显示PRRT在约80%接受治疗的患者中带来生存和症状缓解的获益,最终一项正式随机对照试验证实PRRT安全有效,是激素难治性NETs的首选治疗。

要点

  • PRRT在约80%接受治疗的患者中带来生存和症状缓解的获益。
  • 正式随机对照试验证实PRRT安全有效,是激素难治性NETs的首选治疗。
  • PRRT的临床转化历经十余年波折,早期研究存在方案模糊和数据缺失。

核心结论

  • PRRT在约80%接受治疗的患者中带来生存和症状缓解的获益。
  • 正式随机对照试验证实PRRT安全有效,是激素难治性NETs的首选治疗。

研究设计与样本

  • 本文为综述,回顾PRRT在播散性NETs中从学术构想到临床实践的发展历程。

主要发现

  • PRRT的临床转化历经十余年波折,早期研究存在方案模糊和数据缺失。
  • 逐渐积累的证据显示PRRT在约80%接受治疗的患者中带来生存和症状缓解的获益。

关键数值与推荐

  • 正式随机对照试验比较PRRT与高剂量生长抑素,证实PRRT安全有效且为激素难治性NETs的首选治疗。

临床怎么用

  • PRRT可作为激素难治性NETs的首选治疗。

局限性

  • 早期研究存在方案模糊和数据缺失,部分基础科学在首次人体研究之后才完成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of peptide receptor radionuclide therapy (PRRT) in disseminated neuroendocrine tumors (NETs) has been a long and protracted process. The idea was born within nuclear medicine academia but its translation to clinical practice has been marked by misunderstanding of the rigors of the processes used in drug registration. There were several false starts and some of the required basic science did not occur until after first in man studies. The standard process of preclinical, phase 1, 2 and 3 clinical trials were sometimes blurred and the required data including the assurances that patients were studied on protocol was missing from subsequent publications. Despite this there was a growing conviction and increasing evidence that the use of PRRT had a positive benefit in both survival and symptom relief in about 80% of treated patients. After a decade and a half of false starts and incomplete data a formal randomized controlled trial was conducted comparing PRRT with high dose somatostatin which clearly proved that PRRT was both safe, effective and the treatment of choice in hormone refractory NETs.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Buscombe JR. Evidence Base for the Use of PRRT. Semin Nucl Med. 2020. PMID: 32768004. doi:10.1053/j.semnuclmed.2020.04.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。